ImageneBio, Inc.

ImageneBio, Inc. announced the appointment of Matt Robbins as General Counsel, effective July 7, 2026. Robbins, an experienced life sciences attorney with over 15 years of corporate, securities, and transactional experience, will oversee the company's legal, corporate governance, intellectual property, and compliance functions. This strategic hire is intended to support ImageneBio as it advances its lead candidate, IMG-007, through Phase 2 clinical programs in atopic dermatitis and alopecia areata, entering a new phase of growth.

ImageneBio, Inc. announced that Robert Lally, its Senior Vice President of Finance and Operations and principal accounting officer, has resigned. His resignation is effective July 22, 2026. The company stated that Mr. Lally's departure was not due to any disagreement and that a search for his replacement is underway.

ImageneBio, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders approved an amendment to the 2025 Equity Incentive Plan. This amendment increases the aggregate number of shares authorized for issuance under the plan by 850,000 shares and modifies the calculation for the annual automatic share reserve increase. Additionally, stockholders elected two Class II directors, David P. Bonita, M.D. and Joseph P. Slattery, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026.

ImageneBio, Inc. announced that its CEO, Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 PM EDT. Management will also hold one-on-one meetings. The company is a clinical-stage biotechnology firm focused on immunological, autoimmune, and inflammatory diseases, with its lead program IMG-007 in Phase 2b for atopic dermatitis and planning a Phase 2 study for alopecia areata.

ImageneBio, Inc. reported a net loss of $10.6 million for the first quarter of 2026, a significant increase from $6.1 million in the prior year. The company's cash used in operating activities more than doubled to $14.8 million. This follows the July 2025 merger of Ikena Oncology and Legacy Inmagene, which was accounted for as a reverse recapitalization, and a concurrent $75.0 million PIPE financing. The company also disclosed a material weakness in internal control over financial reporting and expects to incur significant losses, requiring substantial additional funding.

ImageneBio reported its first-quarter 2026 financial results, including a net loss of $10.6 million. The company successfully completed a private placement in April 2026, raising approximately $30 million, which extends its cash runway into Q1 2028. ImageneBio also provided updates on its lead program, IMG-007, progressing its Phase 2b ADAPTIVE trial for atopic dermatitis and planning a Phase 2 study for alopecia areata in 2026.

ImageneBio, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 16, 2026, at 9:00 a.m. Eastern Time. Stockholders will vote on the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, and the approval of an amendment to the 2025 Equity Incentive Plan to increase authorized shares by 850,000. The company was formed in July 2025 through a merger between Ikena Oncology, Inc. and Inmagene Biopharmaceuticals, which also involved a 1-for-12 reverse stock split and a $75.0 million PIPE financing.

ImageneBio, Inc. has entered into a Securities Purchase Agreement with institutional and accredited investors for a private placement. The company plans to sell pre-funded warrants to purchase up to 5,770,335 shares of common stock at a purchase price of $5.199 per warrant share, aiming to raise approximately $30 million in gross proceeds. The warrants will have an exercise price of $0.001 per share and will be exercisable immediately, providing capital for the company's operations.